Stockholders' Equity (Common Stock) (Detail Textuals 1) (USD $) Share data in Millions, unless otherwise specified	1 Months Ended	9 Months Ended		3 Months Ended	1 Months Ended		3 Months Ended	9 Months Ended	3 Months Ended			1 Months Ended	3 Months Ended	9 Months Ended
	Sep. 30, 2012	Sep. 30, 2014	Mar. 31, 2014	Mar. 31, 2014 Director	May 31, 2014 Consultants	Apr. 30, 2014 Consultants	Mar. 31, 2014 Consultants	Sep. 30, 2014 Consultants	Mar. 31, 2014 Employees and board members	Mar. 31, 2014 Scientific advisory board members	Mar. 31, 2014 2012 compromise and release agreement	Sep. 30, 2014 2012 compromise and release agreement Vendor	Mar. 31, 2014 Novosom	Sep. 30, 2014 Novosom
Stockholders' Equity [Abstract]
Number of voting right		One vote
Value of shares issued to landlord	1.5
Fair value of shares to be issued			$ 1,900,000
Stockholders Equity Note [Line Items]
Description of consideration for sub-licensed lipid-delivery technology														As part of the asset purchase agreement that we entered into with Novosom in July 2010, we are obligated to pay Novosom 30% of any payments received by us for sub-licensed SMARTICLES® technology. The consideration is payable in a combination of cash (no more than 50% of total due) and common stock (between 50% and 100% of total due), at our discretion.
Shares issued as consideration for sub-licensed lipid-delivery technology				0.08		0.03	0.03	0.03	2.70	0.10			0.96
Value of shares issued for services				30,000		30,000	10,000	30,000	1,000,000	30,000			1,500,000
Number of share issued to vendor											0.1
Value of share issued to vendor											10,000
Payment per month of common shares					5,000
Number of shares issued in settlement of outstanding payable												0.05
Fair value of shares issued in settlement of outstanding payable												$ 60,000